Exemplos de uso de Adverse effect level em Inglês e suas traduções para o Português
{-}
-
Medicine
-
Colloquial
-
Official
-
Financial
-
Ecclesiastic
-
Ecclesiastic
-
Computer
-
Official/political
During lactation, the no adverse effect level in the offspring was 5 mg/kg/day.
Adverse effect levels ranged from 1.6 to 13 times the expected clinical exposure.
During lactation, the no adverse effect level in the offspring was 5 mg/kg/day.
In animal studies(rats)5 mg/kg was the observed NOAEL(No Observed Adverse Effect Level) for embryotoxicity.
The no observed adverse effect level in this study was 0.8 mg/kg b.w.
C-cell hyperplasia andadenoma were seen at all doses in rats and a no observed adverse effect level(NOAEL) could be not defined.
During lactation, the no adverse effect level in the offspring was 5 mg/kg/day.
In the subcutaneous fertility study in rats, while no effects were reported in males, in females, fertility was impaired and a NOAEL(no observed adverse effect level) of 5 mg/ kg was identified.
The NOAEL(No Observed Adverse Effect Level) was 3600 mg/kg/day for pregnant female rats(x 12 the MRHD on a mg/m2 basis) and.
Plasma exposures based on free fraction of active substance, at the no observed adverse effect levels ranged from 1.6 to 13 times the expected clinical exposure.
The no observed adverse effect level(NOAEL) for these findings were below human clinical exposure levels at intended therapeutic dose.
These findings indicate that combined exposure could modify the Lowest Observed Adverse Effect Level LOAEL and the No Observed Adverse Effect Level NOAEL of exposure to organic solvents.
The No Observed Adverse Effect Levels(NOAEL) for these findings were either subtherapeutic or up to 2.6-fold human clinical exposure based on AUC.
This study aimed to evaluate the reproductive toxicity of agnps in the selected parameters in a dose response curve on which the higher dose corresponded to loael(lowest observed adverse effect level) previously established(15¿g/kg) in prepubertal wistar rats as experimental model.
The exposure in rats at the no observed adverse effect level(NOAEL) was less to only slightly higher than the human exposure based on the AUC.
The observed adverse effect level for embryo-foetal toxicity in this study was 10 µg/kg/day, which corresponded to a systemic exposure of approximately 3- 5 times the exposures observed in patients treated with the clinical dose.
Major toxicity findings in mice and dogs following repeated dosing for up to 9 months were the gastrointestinal, haematopoietic, reproductive, skeletal and dental systems,with No Observed Adverse Effect Levels(NOAEL) approximately equivalent to or below expected human exposure at the recommended clinical starting dose based on AUC levels. .
The No Observed Adverse Effect Level(NOAEL) was 0.1 mg/kg/day 0.5-fold exposure ratio relative to a 4 mg clinical dose.
The No Observed Adverse Effect Level(NOAEL) for female fertility was 10 mg/kg/day 20 times the maximum human exposure after dermal application.
The AUC at the no observed adverse effect level(NOAEL) for these effects was below the human exposure at the recommended clinical dose.
At the No Observed Adverse Effect Level(NOAEL) of 0.5 mg/eye in monkeys the systemic exposure was 42- and 56-fold higher based on Cmax and AUC, respectively.
Exposure at the no observed adverse effect level(NOAEL) was similar to(rabbit) or 4 times(rat) the systemic exposure in humans 10, 10, 20 mg/kg/day.
The NOAEL(No Observed Adverse Effect Level) was 3600 mg/kg/day for pregnant female rats(x 12 the MRHD on a mg/m2basis) and 1200 mg/kg/day for fetuses.
These no observed adverse effect level(NOAEL) doses were associated with systemic exposures up to 2.5 times greater than anticipated clinical exposure.
The NOAEL(No Observed Adverse Effect Level) was 3,600 mg/kg/day for pregnant female rats(x 12 the MRHD on a mg/m2 basis) and 1,200 mg/kg/day for fetuses.
The embryo-foetal no-observed adverse effect level(NOAEL) for sacubitril was at least 750 mg/kg/day in rats and 200 mg/kg/day in rabbits 2.2-fold the MRHD on the basis of LBQ657 AUC.
The no observed adverse effect level(NOAEL) for effects on reproduction in females(100 mg/kg/day) was about 16-times the maximum human recommended dose on a mg/m2 basis.
Systemic exposure at No Observed Adverse Effect Level for teratogenic effects in rats and rabbits was of the same magnitude or lower as found at therapeutic doses in patients.
The No Observed Adverse Effect Level(NOAEL) at 15 mg/ kg/ day in rats, is equivalent to an AUC which is considerably higher(x 15000) than the human exposure after ingestion of Circadin 2 mg.
The no observed adverse effect level for embryo-fetal toxicity in this study was 10 μg/kg/day, which corresponded to a systemic exposure of approximately 3-5 times the exposures observed in patients treated with the clinical dose.